Practical Tips After U.S. Supreme Court’s Hikma v. Amarin Case
Executive Summary On June 4, 2026, the U.S. Supreme Court unanimously reversed the Federal Circuit in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., holding that Amarin failed to plausibly plead induced infringement under 35 U.S.C. §271(b). The decision represents the most significant Supreme Court guidance on skinny-label induced infringement since Caraco and provides substantial […]